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ABSTRACT

This thesis research focuses on the interaction of gold(I) thiolates with the disulfide
bonds in proteins, using insulin as a model protein. Insulin contains three disulfide bonds
that can break apart during thiol-disulfide exchange reactions. The goal of this research
was to compare the reactivity of aromatic thiols and gold(I) thiolates in thiol-disulfide
exchange reactions with insulin. When the disulfide bonds in insulin are cleaved, a
suspension of the beta chain particles forms, which scatters 650 nm light, therefore
making it convenient to monitor the reaction using UV-Vis spectroscopy. The rate of
formation of the colloidal suspension is taken to be directly proportional to the rate of
disulfide bond breakage, as reported by Lees, et al.1 who studied the ability of aromatic
thiols to catalyze the reaction of dithiothreitol (DTT) and insulin. The project began by
measuring the relative rate of the reaction between 4-mercaptobenzoic acid, DTT and
insulin vs DTT and insulin, which was also done by the Lees research group. All
reactions were conducted at room temperature in pH 6.5 phosphate buffered solution. The
rate of disulfide bind cleavage in the reaction of 4-mercaptobenzoic acid, DTT and
insulin was 1.7 times faster than the reaction of DTT and insulin. This is consistent with
the relative rate of 1.6 reported by Lees, et al.1 and provided confidence that using the
light scattering technique described by Lees, et al. to monitor the reactions with insulin
was a viable method in our lab. Another experiment was conducted to see whether 4mercaptobenzoic acid would react with insulin by itself; however, this reaction did not
produce a colloidal suspension within a 24-hour period of time, which suggests that 4mercaptobenzoic acid does not cleave the disulfide bonds in insulin in the absence of
DTT. The reaction between 2-mercaptopyridine (Spy), DTT and insulin was also

investigated, and it was determined that 2-mercaptopyridine behaves similarly to 4mercaptobenzoic acid. The next set of experiments was conducted to determine the effect
of replacing aromatic thiols with gold(I) thiolates. Addition of Et3PAu(Spy) to a solution
of DTT and insulin caused cleavage of the disulfide bonds in insulin, as observed by an
increase of light scattering at 650 nm. The shape of the absorbance (intensity of light
scattering) vs. time graph suggests two or more possible competing mechanisms. This is
further supported by the observation that Et3PAu(Spy) reacts with DTT and insulin
separately. In the reaction of Et3PAuSpy and insulin, there is formation of a colloidal
suspension while in the reaction between Et3PAuSpy and DTT, 2-mercaptopyridine is
produced, as evidenced by UV-Vis and 1H NMR spectroscopy. The findings of the study
suggest that Et3PAu(Spy) undergoes a thiol disulfide exchange reaction with insulin,
causing precipitation of the β-chains. Furthermore, this reaction occurs in the absence of
DTT, which is different than the reactivity of aromatic thiols. It is not known whether the
Et3PAu moiety binds to one of the insulin chains or whether further reaction occurs.
Additional studies should be done to deduce the mechanism of the reaction. Et3PAuCl
was also shown to react with insulin, resulting in the formation of a precipitate. Since
Et3PAuCl cannot undergo thiol disulfide exchange, it is suggested that Et3PAuCl interacts
with other donor atoms such as histidine residues in insulin, instead of interacting with
the disulfide bonds, but further studies should be done to deduce the mechanism of the
reaction.
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INTRODUCTION

Insulin contains three disulfide bonds that can break apart during thiol-disulfide exchange
reactions, forming a suspension of the beta chain particles, which scatters 650 nm light,
therefore making it convenient to monitor the reaction using UV-Vis spectroscopy, where
the rate of formation of the colloidal suspension is taken to be directly proportional to the
rate of disulfide bond breakage. Aromatic thiols have been shown to increase the rate of
disulfide bond breakage in the reaction between dithiothreitol (DTT) and insulin, where
DTT and the aromatic thiol can act as redox buffers. A redox buffer is composed of a
redox couple; in this case a reducing thiol and corresponding oxidized disulfide. A redox
buffer is analogous to an acid-base buffer in that a species that is in abundance in solution
will be neutralized by the corresponding component of the redox couple2. The same way
that the conjugate acid in a buffer neutralizes an added base, thiol reduces an added
oxidant and disulfide oxidizes a reduced species. A redox buffer is an aide in protein
folding. In terms of physiology, the ratio of thiol to disulfide is an important factor in
helping to maintain redox homeostasis for healthy functioning of the organism. For
example, glutathione (GSH) is the most abundant antioxidant in aerobic cells, present in
micromolar concentrations in bodily fluids and millimolar concentrations in tissue3. GSH
is critical for protecting the brain from oxidative stress, with a normal percent of GSH
compared to the corresponding disulfide (GSSG) of 98%3. This ratio of GSH/GSSG is
reduced in neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s
disease3. The abundant research that has been conducted on glutathione ratios in humans
shows that the ratio is an important factor in the development of disease. Thus, it is
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important to study redox buffers as potential ways of understanding the mechanisms of
these diseases. The following study was conducted to observe the effect of gold thiolates
on biological disulfides, using insulin as a model protein disulfide. It was predicted that
gold thiolates might act as a redox buffer, much in the same way that an aromatic thiol
would in the reaction between DTT and insulin.

Goals of Research
The major question of this study is concerned with how gold thiolates may be interacting
with biological disulfide proteins such as insulin. The hypothesis entails the use of gold
thiolate as a redox buffer, much in the same way that an aromatic thiol/thiolate can act as
a redox buffer in the reaction between insulin and DTT (where DTT also acts as a redox
buffer). The Lees research group has done extensive research on the aspects of a protein
folding redox buffer that would be most advantageous for the rate and yield of protein
folding, and has specified the following criteria for advantages to the redox buffer:

1) Low thiol pKa (strongly acidic thiol, weakly basic thiolate-close to physiological
pH), a pKa of approximately 1 unit less than the pH of the solution has been
found to be optimal for protein folding, because of the enhanced reactivity of the
thiolate4
2) Low reduction potential (allows the redox buffer to exist as a nearly 50:50
mixture of thiol and disulfide for efficient protein folding)4
3) Dithiol over a monothiol (dithiols discourage forming long-lived mixed disulfides
between the folding catalyst and the protein of interest)
4) Aromatic over aliphatic increases the rate of folding by at least three times
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The Lees research group had published a paper in 2012 on the synthesis and protein
folding rates of aromatic dithiols, combining the two advantages (dithiol and aromatic) to
make a power duo5, but they have not attempted to do the same for metals, such as gold.
Before such attempts are made it is important to see if a gold thiolate would react with a
protein disulfide and if so, if it would act as a redox buffer. The plan is to conduct a set of
UV-Vis and 1H NMR experiments to investigate the reactions of gold complexes, thiols
and insulin to observe possible interactions between the reactants that would hint at the
possibility of gold thiolate acting as a redox buffer. Starting with the reaction between
insulin, DTT and an aromatic thiol, the goal is to replace the aromatic thiol with a gold
thiolate and observe the interaction. Along the way, several other experiments will be
conducted, such as the reaction between DTT and a gold thiolate, to look at possible side
reactions.

Gold in Medicine
Gold has been used medicinally to treat various diseases for many centuries. The use of
gold dates as far back as 2500 BC, the earliest application of gold as a therapeutic in
China6,7. The modern interest in gold is attributed to the discovery by Robert Koch in
1890 that gold cyanide inhibits the growth of Tubercle bacillus, the bacterium that causes
tuberculosis in humans6,7. Despite the lack of experimental evidence and the toxicity of
the compound, the “gold decade” followed (1925-1935), in which intravenously
administered gold(I) thiolate salts were used for the treatment of tuberculosis6,7. During
this time, gold therapy was also found to reduce joint pain in a group of non-tubercular
patients, which led Jacques Forestier, a French physician, to research the use of gold
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compounds as a treatment for rheumatoid arthritis6,7. Subsequently, in 1960 a trial
concluded that gold drugs have a beneficial effect for the treatment of rheumatoid
arthritis6,7. Some gold thiolate drugs that were first introduced in the 1920’s are still used
today (Figure 1). These drugs primarily slow the progression of disease. Auranofin
(Figure 1.3) is an orally active drug. Despite early indications that auranofin offered
significant advantages over injectable Au(I) thiolates, it was later proven that auranofin
is, in fact, less effective6,7. Because of this, oral gold is now rarely used clinically6,7.

Figure 1: Examples of gold(I) drugs used for the treatment of rheumatoid arthritis (1) sodium
aurothiomalate (Myocrisin), (2) aurothioglucose (Solganol), (3) tetraacetyl-B-d-thioglucose gold(I)
triethylphosphine (auranofin). The 1:1 Au-S drugs (1 and 2) are polymers6.

Gold Thiolates as Treatment for Rheumatoid Arthritis
Specifically, gold thiolates are used to treat rheumatoid arthritis, which is a chronic
inflammatory disease characterized by the migration of activated phagocytes and
leukocytes into synovial tissue, which causes progressive destruction of cartilage and
bone and joint swelling6,7. There is evidence that gold thiolates have several different
ways they help treat the disease, where most cases involve interaction with protein Cys
(or Sec) residues6,7. Recent studies on gold thiolate mechanisms have focused on their
effects on macrophage signal transduction and the induction of inflammatory
cytokines6,7. Cytokines are low molecular weight peptides, proteins or glycoproteins6,7.
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Gold compounds can play a role in each of the phases of the immune reaction, such as the
initiation stage6,7. During this stage, gold is taken up by macrophages and inhibits antigen
processing6,7. This likely happens by binding peptide antigens that contain cysteine and
methionine residues6,7. Gold then accumulates, in the form of S-Au(I)-S, in the lysosomes
of synovial cells and macrophages, forming aurosomes (gold laden deposits)6,7. At the
level of transcription, gold(I) drugs downregulate a range of proinflammatory genes by
inhibiting transcriptional activities of the NF-kB and AP-1 (Jun/Fos) transcription
factors7. In general, AP-1 controls the expression of genes for collagenase and the
cytokine IL-2, and NF-kB controls transcription of other inflammatory mediators,
including TNF-α, IL-1, and IL-67. Additionally, gold drugs act at the T-cell level, and
have been shown to inhibit osteoclast bone resorption, recently attributed to the inhibition
of the cathepsins6,7. Rheumatoid arthritis patients also have elevated levels of copper that
can be correlated to the severity of the disease6,7. This might be because gold drugs could
interfere with copper homeostasis by binding Cu(I) responsive transcription factors and
other Cu(I) transport proteins6,7.
Gold drugs are classified as DMARDS (disease-modifying anti-rheumatic drugs). Despite
the fact that DMARDS are one of the only ways to place the inflammatory disease in
remission, they are slow acting, sometimes requiring 3-6 months for patients to
experience improvement in joint function and reduction in swelling8.

Other Medicinal Uses of Gold
In addition to being used as rheumatoid arthritis medications, Au(I) and Au(III)
compounds have also been used and designed with an aim of targeting cellular
components that are implicated at the onset or progression of cancers, as well as viral and
5

parasitic diseases6,7. In the mid 1980’s auranofin (Figure 1.3) was shown to inhibit the
growth of cultured tumor cells6. Since then, a large variety of Au(I) and Au(III)
complexes has been developed that show some kind of inhibition of tumor growth and
have been shown to have potential as cancer treatments6. In addition, various Au(I)
antitumor compounds, including auranofin, have been shown to overcome resistance to
cisplatin and other anticancer drugs7. Many mechanistic studies indicate mitochondria as
the biological targets for gold antitumor compounds since mitochondria play a key role in
the regulation of apoptosis and the regulation of the intracellular redox state7.

Gold-based compounds also showed early promise as a less toxic and less drug resistant
version of an AIDS cure6. A variety of Au(I) and Au(III) compounds have been
investigated as anti-HIV agents6. Gold-based compounds also offer great potential in the
field of affordable antiparasitic drugs6. This is because they can bind thiol and selenol
proteins that have been identified as drug targets in trypanosomes (African sleeping
sickness, Chagas’ disease and leishmaniasis), malaria-causing plasmodia, and
schistomiasis6. In conclusion, there is great potential for application of the gold complex
mechanisms for treatment of a variety of diseases, and for the design of new gold
complexes for diseases with the same target complexes.

Gold Compounds
Gold(I) (5d10) is a large ion with a low charge and is a “soft” Lewis acid, therefore
forming its most stable complexes with “soft” ligands such as CN, S-donors, P-donors
and Se ligands7. Linear, two-coordination is most common for gold(I)7. The highest
affinity gold(I) has is for thiols with the lowest pKa values7.
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There are examples in the literature of gold(I) complexes facilitating disulfide bond
cleavage in biologically relevant systems9,10. Early studies on auranofin (Figure 1.3)
show that its highly reactive nature towards protein thiols limits its antitumor activity in
vivo6. Subsequently, the development of Au(I) complexes with chelated diphosphines
such as [Au(dppe)2]Cl (Figure 2) began with the goal of reducing the high thiol reactivity
of auronofin and similar compounds. The behavior of this compound is consistent with
that of the class of antitumor agents known as delocalized lipophilic cations (DLCs), that
accumulate in the mitochondria of tumor cells driven by one of the characteristic features
of some cancer cells- an elevated mitochondrial membrane potential6. It was found that
the high lipophilicity of these compounds results in severe toxicity as a consequence of
the inability of the compounds to differentiate between tumorigenic and non-tumorigenic
cells, concentrating in both and causing general membrane permeabilization6. A
compound was designed to retain the lipophilic cationic properties of the tetrahedral bischelated complexes that allow accumulation into the mitochondria, but reduce the
cytotoxicity of the compound, so it can be used as an anti-tumor agent1. This compound
was [Au(d2pypp)2]Cl, and recent findings have shown that the compound is selectively
toxic to breast cancer cells but not normal breast cells.
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Figure 2: Examples of lipophilic cationic gold(I) antitumor compounds6.

Similar compounds were used as the focus of this investigation. Specifically, Et3PAuCl,
Et3PAuSpy (where py is a 2-pyridyl group), and Et3PAuSba (where ba is a benzoic acid
group) (Figure 3).

Figure 3: From left to right: structures of Et3PAuSpy, Et3PAuSba and Et3PAuCl respectively.
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Et3PAuSpy has been shown to have antitumor effects in vivo (mice) and has also been
shown to have a similar cytotoxicity to auranofin in vitro (P388 leukemia cells)11.
Et3PAuCl was less cytotoxic in vitro but had the same maximally tolerated dose in tumor
bearing mice, on a daily x5 ip (intraperitoneal injection) regimen11. Between the two
compounds, Et3PAuSpy had a larger antitumor effect (46% median life span (ILS)
increase in mice inoculated ip with 106 P388 leukemia cells, given ip on days 1-5) versus
Et3PAuCl (36% ILS increase), where an ILS value of ≥40% represents cell kill sufficient
to result in net reduction in tumor cell burden at the end of therapy; with a level of
significance of p≤0.0511. Early mechanistic studies provided evidence that Et3PAuCl
affects mitochondrial function and these results are consistent with an antitumor
mechanism involving the induction of mitochondrial-dependent apoptosis pathways7.
It is of interest to note that some studies have hypothesized that the more reactive the
gold compound is towards disulfide bonds, the more toxic it probably is9. This hypothesis
stems from the observation that the more a compound is like auranofin structurally, the
more easily it breaks disulfide bonds and the likelihood that the biological activity of the
compound will be similar to auranofin increases, therefore making the compound
supposedly more toxic.

Thiols
The thiols used in this study include dithiothreitol (DTT), 4-mercaptobenzoic acid (Sba),
and 2-mercaptopyridine (Spy) (Figure 4).
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Figure 4: Thiols used in this study from left to right: dithiothreitol (DTT) (pKa=9.2, 10.1), 4mercaptobenzoic acid (Sba) (pKa=5.95), and 2-mercaptopyridine.

It is known that 4-mercaptobenzoic acid increases the activity of protein disulfide
isomerase (PDI) by a factor of three12. PDI is a eukaryotic enzyme that has many
functions during the folding of disulfide-containing proteins (Figure 5)12. In terms of a
mechanism, PDI functions in the same way as an aromatic thiol when in solution with a
protein disulfide. It is also known that 4-mercaptobenzoic acid catalyzes the reaction
between insulin and DTT1. PDI contains two active sites, each of which has a CXXC
motif, where X is any amino acid and C is cysteine4. The two cysteines form a 14membered ring upon oxidation to the disulfide4.
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Figure 5: Structure of protein disulfide isomerase (PDI). Backbones are indicated as rounded ribbons,
which are part of α-helices or β-sheets. The string-like filaments are parts of loops and turns (different kind
of protein organisation). Each color is a different chain. The chains come together to form PDI. Picture
constructed using Chimera viewing software (PDB file:2BJX, protein disulfide isomerase)

DTT itself can act as a buffer by having a mix of reduced thiol DTT and oxidized
disulfide DTT, which forms a redox buffer, a mix of thiol (RSH) and corresponding
disulfide (RSSR)1,12. Dithiols, like DTT, are proposed to improve protein folding by
shortening the lifetime of kinetically stable mixed disulfide formed between the protein
and the small molecule thiol13. Having two thiols makes it easier for DTT to displace the
mixed disulfide intramolecularly instead of intermolecularly, as is the case for
monothiols, where intramolecular displacement is proposed to be more rapid13. DTT has
been studied extensively for its reducing capabilities when in contact with disulfides. As
the reduced DTT is not UV-active, one can use the oxidized DTT formed in the process
of thiol-disulfide exchange to quantify the number of disulfide bonds broken by
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measuring the absorbance at 310 nm, where the molar absorption of DTT is 40% of its
maximum absorbance14. The number of SH groups per mole protein was measured by
rapid gel filtration with the method of Ellman (see source 10 citation 8). DTT has also
been studied for its proposed activities in stimulating the insulin receptor/kinase, which is
the initial event of insulin action (binding of insulin to its receptor on the cell surface of
target cells15. Some studies focused on the calorimetric measurements of the reduction of
insulin by DTT, which allows to approximate the number of protons attached to cysteine
residues in insulin after reduction, thereby approximating the degree to which the
disulfide bonds in insulin have been reduced16,17.
An advantage that PDI has over monothiols is the availability of two thiols at each active
site. There is a proposed advantage for dithiols that has been termed the “escape
mechanism” that allows the dithiol to discourage the formation of long-lived mixed
disulfides between the folding catalyst and the protein of interest (Figure 6)4.

Figure 6: Proposed advantage of having two thiols in each active site of PDI, the escape mechanism4
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In 2012 the Lees group published a paper detailing the synthesis of aromatic dithiols that
were used as potential redox buffers for the folding of inclusion bodies (protein
aggregates) into the native functional form of the protein disulfide5. The aromatic dithiols
significantly increased the folding rate and also the yield of functional protein compared
to aliphatic monothiols, aliphatic dithiols and even aromatic monothiols5. The Lees group
has also recently proposed that aromatic thiols with an elongated alkyl group on the
aromatic ring are expected to increase interactions with the hydrophobic core of disulfide
containing proteins during folding, allowing easier access to buried disulfide bonds18.

Insulin
Overview
Insulin is a hormone that plays an important role in the regulation of vertebrate
metabolism19. It is also the most important pharmaceutical peptide for the treatment of
diabetes20. This project uses insulin as a model protein disulfide because it contains three
disulfide bonds that can break apart during thiol-disulfide exchange reactions, forming a
suspension of α- and β-chain particles1,21, which scatters 650 nm light22 therefore making
it convenient to monitor the reaction using UV-Vis spectroscopy. It has been shown that
these unfolded chains expose their hydrophobic surfaces and bind together through
hydrophobic interactions, eventually forming large, insoluble aggregates20. The
wavelength of 650 nm was picked specifically because it shows a linear relationship
between S-S bond reduction and precipitation22. Insulin contains 1 intra-chain disulfide
bond on the α-chain (A6-A11) and 2 inter-chain disulfide bonds (A20-B19, A7-B7) that
hold the α and the β chains together (Figure 7). It was found by Holmgren that the rate of
precipitation of the insulin chains was much higher at pH 6.5 than at pH 8.022. This is
consistent with the fact that insulin is less soluble at lower pH.
13

Figure 7: Structure of insulin, showing the α-chain (blue), β-chain (green) and the Cys-Cys disulfide bonds
(pink). Picture constructed using Chimera viewing software (PDB file: 6QQ7, bovine insulin).

Typically, disulfide bonds are formed by the oxidation of cysteine residues and provide
stability to the protein by minimizing the entropy of the unfolded state as they crosslink
one part of the protein with another4. This oxidative protein folding mechanism mainly
occurs inside the endoplasmic reticulum of eukaryotes4. All three disulfide bonds are
essential for the receptor binding activity of insulin but contribute differently to the
overall structure23. Deletion of the second interchain disulfide bond (A20-B19) has the
most substantial influence on the structure as indicated by the loss of ordered secondary
structure, increased susceptibility to proteolysis, and greatly reduced compactness23. This
is most likely due to the fact that this bridge packs within itself a cluster of conserved
aliphatic and aromatic side chains in the hydrophobic core19. The deletion of the
intrachain disulfide bond causes the least change in the structure23. It is also known that
the disulfide bonds are formed sequentially in the order A20-B19, A7-B7 and A6-A11 in
the folding pathway of proinsulin (where A and B are the α and β chains and the number
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designates placement of connecting amino acid in the amino acid sequence of insulin)
(Figure 8).19,23

Figure 8: Bovine insulin amino acid sequence, with disulfide bonds indicated as a solid line24

These disulfide bonds are formed when proinsulin, the precursor to insulin, is folded in
the endoplasmic reticulum prior to packaging into secretory granules in pancreatic β-cells
which already contain the requisite processing enzymes23,25. The adult hormone is stored
as Zn2+ stabilized hexamers (Figure 10) within these granules19. The hexamers precipitate
in the granules, which increases the stability of mature insulin, making it inaccessible to
proteases26. The hexamers dissociate upon secretion into the portal circulation, since only
the monomeric form of insulin is able to bind its receptors in the liver and adipose
tissue19,26. The zinc-mediated assembly may represent a defense against toxic misfolding
in the secretory granule (Figure 9)19.

15

Figure 9: β-cell biosynthetic pathway for the packaging of insulin19.

Figure 10: View of insulin dimer coordinated by histidine residues to 2 Zn2+ atoms (grey spheres). By
combining with two other dimers, insulin forms a zinc-stabilized hexamer. The hexamer also contains a
Ca2+ cation for increased stability. Picture constructed using Chimera viewing software (PDB file: 2ins).

The disulfide bonds that hold the two chains of insulin together are post translational
modifications involved in stabilizing the native structure27. Research has shown that it is
not only the interchain disulfide bonds that are broken in a reduction reaction of insulin,
but when treated with thioglycolate solutions at pH 5, the major reaction that occurs is the
16

cleavage of the intrachain disulfide bond on the α-chain21. It is not clear which of the
three total disulfide bonds in the structure are more accessible to reagents and is therefore
the likely candidate to be reduced first, although some researchers suppose that the
intrachain disulfide bond will be reduced first21. Other researchers have pointed out that
the rate of electrolytic reduction of the two interchain bonds was found to be significantly
faster than that of the intrachain disulfide bond28. It seems that the likelihood of being
reduced first depends on the experimental conditions and reagents used.
In terms of accessibility, it seems like the A7-B7 inter disulfide bond is most accessible
(exposed) based on a ball and stick model in Figure 11 (right). Additionally, because the
hydrophobicity surface is pointed out (remember that B7 is surrounded by leucine and
glycine, which are both hydrophobic) the molecule will want to expose the hydrophilic
cysteine in the same way a micelle will want to fold the hydrophobic tails in a lipid
bilayer inside itself while exposing the hydrophilic heads. On the other hand, the A20B19 and A6-A11 disulfide bonds have hydrophobicity pockets, which might be big
enough to fit a gold thiolate molecule inside but are not quite as accessible.
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Figure 11: Hydrophobicity surface of insulin, where the color gradient is determined by the Kyte-Doolittle
scale, where blue is hydrophilic, red is hydrophobic and white is in between. Picture at right shows the
cysteine residue hydrophobicity surface removed. Picture constructed using Chimera viewing software
(PDB file: 6QQ7, bovine insulin).

Each amino acid residue has an alpha carbon and two Ramachandran angles: ψ-psi and φphi, the only two bonds that are available to freely rotate in the backbone, and therefore
define the conformation of the protein. ψ is the angle between Cα and the carbonyl carbon
(Figures 12 and 13), while φ is the angle between Cα and the amide that joins two
residues together (Figures 14 and 15). The Ramachandran plot can be seen in Figure 16.
Ψ and φ are limited by steric hinderance, as no two atoms may occupy the same space,
and these regions of the Ramachandran plot will therefore be empty of any residues.
These regions are not allowed by sterics.
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Figure 12: Rotation of psi bond29

Figure 13: Rotation of psi bond looking down the alpha carbon with the carbonyl carbon at the back29
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Figure 14: Rotation of phi bond29

Figure 15: Rotation of phi bond looking down the amide nitrogen with the alpha carbon at the back29
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Figure 16: Ramachandran plot for bovine insulin. Cysteine residues colored red, all other residues blue.
Green lines show the probability contour based on a reference set of high-resolution proteins. Graph
constructed using Chimera viewing software, picking general amino acid as the probability contour (PDB
file: 6QQ7, bovine insulin).

As can be seen in the Ramachandran plot above, the top three cysteine residues (A11,
A20 and B7) are most likely parts of loops or turns, the less ordered tertiary structures of
proteins, although the general region where they are located (high psi, negative phi)
usually codes for β-sheet as the most likely structure. The bottom three cysteine residues
(A6, B19 and A7) are parts of α-helices. The Ramachandran plot further supports the
structure above as the more likely structure of insulin and shows that in each disulfide
bond of insulin, one of the cysteines is in a turn or loop, while the other is in an α-helix,
making it difficult to judge the accessibility of one disulfide bond over another. However,
it is possible to deduce something from the energetically unallowable regions of the
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Ramachandran plot. One of such unallowable regions spans the horizontal line where ψ is
between -20° and 20° 29. This is the clash between an amide nitrogen and the hydrogen
attached to another amide nitrogen. In comparison to the other steric clashes, this one is
not as energetically unfavorable, yet it still provides some hinderance. The two top
cysteine residues of the α-helix group in the Ramachandran plot are inside that region of
N-H steric hinderance, while the bottom residue (A7) is not. This seems to propose that
the A7 residue would be more stable and therefore unlikely to relieve any steric
hinderance, supporting the notion that it would be the least likely to react with any gold
thiolate compound. But that is only half of the disulfide bond, since gold cannot attack
both sulfurs at the same time and will favor one over the other. The sulfur attacked might
be chosen based on the possibility of alleviation of steric hinderance, which would make
the A7 residue less likely to be attacked.
Combined with the observation that A7-B7 is the most exposed disulfide bond according
to hydrophobicity considerations, the prediction that A7 is less likely to be attacked
suggests that it might be possible to reason about the accessibility of the disulfide bonds
as well as the likelihood that they will be reduced. However, any sort of conclusion is
beyond the scope of this discussion.
The Lees group has recently proposed that aromatic thiols with an elongated alkyl group
on the aromatic ring are expected to increase interactions with the hydrophobic core of
disulfide containing proteins during folding, allowing easier access to buried disulfide
bonds18. This could be an advantage for the insulin disulfide bonds that are not as
accessible as A7-B7.
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Reaction Between Insulin and Dithiothreitol
From the DeCollo and Lees study it appears that they use DTT as a way to shift the
equilibrium of the reaction toward reduced insulin1. DTT does this by reducing the
aromatic disulfides formed in the interaction between insulin and an aromatic thiol back
to the starting reactants. The reaction between insulin and an aromatic thiol can be seen in
Figure 17 below. After the thiol reduces insulin, it forms a disulfide which, in the
presence of DTT, is subsequently broken to react again with insulin. Thus, DTT is
shifting the equilibrium of the reaction toward reduced insulin.

Figure 17: Reduction of insulin by aromatic thiol in the absence of DTT1

It is known that DTT significantly alters portions of secondary structural elements of
insulin through aggregation, decreasing α-helical content from 34.8% to 13.2%,
increasing β-sheet content from 16.3% to 26.9% and random coil content from 32.3% to
42.6%20.
In comparison to PDI, 5 to 10 times the weight of an aromatic thiol is needed to match
the rate of the reduction of insulin in the presence of DTT1. However, PDI, the in vivo
catalyst, is expensive and can be difficult to separate from other proteins, thus leaving
potential for aromatic thiols to catalyze the reaction more cheaply and just as effectively1.
It is also a possibility to use PDI and aromatic thiols congruently12.
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Arguably, DTT can also be used to reduce insulin directly, as shown by Holmgren,
during which reaction DTT forms a disulfide (Figure 18). In this reaction, thioredoxin
acts as the redox buffer; however, DTT reduces insulin even without a redox buffer at the
expense of a reduced reduction rate.

Figure 18: Formation of DTT disulfide as a result of thioredoxin catalysis22

An interesting application of the interactions between DTT and insulin is the percent of
insulin binding to tissues that have been treated with DTT. Komori et al. showed that
binding of 125I-labeled insulin to rat liver membranes increased by 21.3% after the tissues
have been treated with 0.5 mM DTT30. Furthermore, in rat adipocyte membranes, insulin
binding was increased by 107.2% when the tissues had been treated with 1.0 mM DTT30.
Both of these experiments showed elevated receptor affinity30. However, in rat and
human erythrocyte membranes, DTT decreased binding in a dose-dependent manner,
showing a decrease in receptor affinity30. This has interesting implications for molecules
with similar biological activities when in contact with insulin to possibly have the same
effect. The importance of insulin binding activity when exposed to DTT lies in that the
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major event of the insulin mechanism in the body is binding to insulin receptors in
tissues. If DTT is impacting the rate of binding, this change might be attributed to the
aggregation of insulin by DTT.
Thiol-Disulfide Exchange
Overview
Thiol-disulfide exchange is an SN2 reaction31. It is bimolecular and the rate of reaction is
dependent on both reactants31. The first step of the reaction is a deprotonation of thiol,
while the second step is the SN2 attack of thiolate on disulfide31. The reaction proceeds
through a transition state with a linear orientation of the three sulfur atoms31. A general
schematic of a thiol disulfide exchange can be seen in Figure 19.

(1) HSR ⇌ -SR + H+
(2) -SR +R’SSR’⇌ -SR’ +RSSR’
Figure 19: Generic thiol-disulfide mechanism

Thiol-disulfide exchange is essential in structural and functional modifications that occur
in many proteins31. The formation of mixed disulfides between glutathione or cysteine
and proteins is thought to play a role in cell signaling and regulatory pathways that are
important in oxidative stress, apoptosis and aging31.

Protein-Folding Thiol-Disulfide Exchange Reactions
When proteins are overexpressed in bacteria, they are isolated as aggregates of inactive
protein known as inclusion bodies, and to obtain the active form of the protein, the
inactive protein is denatured and then folded in vitro1. The folding of disulfide containing
proteins from denatured protein to native protein involves numerous thiol-disulfide
interchange reactions1. A number of these reactions include a redox buffer, which is a
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mixture of a thiol (RSH) and the corresponding disulfide (RSSR)1. A study conducted in
2001 by Todd DeCollo and Watson Lees concluded that aromatic thiols speed up the
thiol disulfide exchange reaction between dithiothreitol (DTT) and insulin, as seen in
Figure 201. The proposed reason for the higher catalytic activity of the aromatic thiols is
the similarity of their pKa to that of the in vivo catalyst, protein disulfide isomerase
(PDI), with lower pKa values correlating to a higher increase in protein folding and
unfolding rates1. It is also known that aromatic thiolates (pKa=5~6) are better leaving
groups than aliphatic thiolates such as glutathione (pKa=8.7), due to their lower thiol pKa
values13. Additionally, aromatic thiolates are better nucleophiles than aliphatic thiolates
with similar thiol pKa values13.

Figure 20: Reduction of native insulin by aromatic thiol and DTT at pH 6.51

Using an aromatic thiol, the rate would be expected to not only increase when folding the
protein, but in the reverse reaction as well. There are many factors that become important
when studying protein folding. In many cases when proteins are overexpressed in
bacteria, they are isolated as aggregates of inactive protein known as inclusion bodies1.

26

To obtain the active version of the protein, the inactive protein is denatured and then
folded1. For proteins containing disulfide bonds (such as insulin) the folding rate is
usually limited by a thiol-disulfide interchange reaction. This reaction occurs in the
protein itself as well as between the protein and the redox buffer, mentioned earlier1. The
reaction occurs in the protein by breaking or forming the two disulfide bonds that hold
the two peptide chains of insulin together, and it occurs between the protein and the redox
buffer by breaking the disulfide bond on the outside of the alpha chain and also probably
interacting with the newly formed thiolates on the inside of the two chains, as seen in
Figure 21. The standard redox buffers, until the DeCollo/Lees study, were
mercaptoethanol and cysteine derivatives such as glutathione1. As a precursor to the
study, DeCollo and Lees sought to design small molecule thiols as redox buffers for
protein folding, basing their predictions on thiol pKa values and inherent nucleophilicity
of PDI1. During their study, they found that, as stated above, aromatic thiols significantly
increased the rate of reaction between DTT and insulin1. They also found that the twostep reduction of protein disulfides to dithiols is an important component of the folding
process as it removes intermediates with mismatched disulfide bonds, as seen in Figure
211.

Figure 21: Folding of a protein with mismatched disulfide bonds1
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As can be seen in the figure, instead of holding the two chains of the protein together, the
mismatched disulfide bonds prevent the protein from being effective, which is
problematic, since only correctly folded proteins are functional. The refolding process
gains native protein, which is fully functional. Since disulfide bonds are the only covalent
bonds formed during in vitro folding, their formation is usually the rate-determining
step32. A number of factors affect the folding rate of a disulfide containing protein with
an aromatic thiol, namely the concentration of thiol in the neutral RSH form, the
concentration of the thiolate anion and the reactivity of the thiolate anion13. The
concentration of thiol in the thiolate form is important because thiolate is the reactive
species in the thiolate-disulfide interchange reaction13. As stated above, the reactivity of
the thiolate is linked to the thiolate pKa: the lower the aromatic thiolate pKa, the higher
the reactivity of the thiolate, although compared to aliphatic thiols with the same pKa, the
aromatic thiols are more reactive13. In short, the thiol must have a small pKa (be
relatively acidic).
A mechanism for the refolding of insulin that was proposed by Gabor Markus predicts
that the chance establishment of the first correct disulfide bond will greatly increase the
chances of the formation of the next correct bond, by a) reducing the degrees of freedom
available for random recombination, and by b) helping to align properly one or more
additional pairs of correct sulfhydryl partners28. However, as insulin may interact not
only with the reducing DTT but also with the RSH/RSSR buffer, the following eight
reactions may be occurring during the in vitro folding of a protein disulfide32 (Figure 22).
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Figure 22: Eight variations of the thiol-disulfide reaction that can occur during in vitro folding of a protein
disulfide with a small molecule thiol (RSH) and a small molecule disulfide (RSSR)32
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The first four of the reactions involve the protein thiolate acting as the nucleophile, while
the last four reactions have the small molecule thiolate (DTT and/or aromatic thiol and/or
gold thiolate) acting as the nucleophile32.
Optimized Conditions for Protein Folding
As found by the Lees research group, the yields of protein folding decrease with
increasing protein concentration, so naturally, folding at low protein concentrations is
advantageous5. However large amounts of refolding solution are needed to refold the
protein, making it impractical on the large scale5. As an efficient strategy, the addition of
folding aids was utilized (usually guanidine hydrochloride, urea, arginine, and glycerol)5.
The proposed method that folding aids utilize for increasing the folding yield is by
interfering with the intermolecular hydrophobic interactions that lead to protein
aggregation during in vitro folding5. While aggregation causes reduced overall yields,
folding aids are a way to increase yield, but folding aids generally decrease the rate of
protein folding5. This is where aromatic dithiols were utilized. Aromatic dithiols were
observed to increase both the rate of folding and overall yield, which has not been
achieved by any other type of molecule so far5. Aromatic thiols are also much more cost
effective compared to glutathione and PDI (aromatic thiols are about 1% the cost of
glutathione)33.

Effect of Disulfide Bond Cleavage on Biological Activity
Studies have shown that disulfide cleavage affects biological activity very drastically23.
The half-maximal inhibition concentration for human insulin was found to be 0.71 nM
(100%), while insulin mutants that had a deleted disulfide bond only had 0.2% of this
activity, with some having a percentage that is even 4 to 5 times smaller than that23.
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Furthermore, the deletion of the disulfide bonds has an effect on the secondary structure
of insulin23. Insulin contains approximately 45% α-helical content, whereas mutants with
a deleted disulfide bond had anywhere from 11 to 22% α-helical content, and one had no
α-helical content at all23.

Gold Thiolate, Disulfide Exchange
Overview
The influence of gold(I) on the mechanism of thiolate, disulfide exchange was studied
thoroughly over the past several years. It was found that gold(I) can indeed participate in
thiolate-disulfide exchange due to several factors, such as gold(I)’s high affinity for
sulfur and selenium31. Cellular targets for gold compounds primarily include cysteine
and/or selenocysteine-containing proteins31. In addition, early studies have shown that
gold accumulates in inflamed synovial tissues, and similarly to other heavy metals, Au(I)
ions lead to expression of thionein31. This and other evidence cited above suggests that
the gold thiolate-disulfide exchange mechanism is important and warrants further study.

The rate law for a gold thiolate-disulfide exchange reaction is overall second order, first
order in gold(I)-thiolate and disulfide31. Electrochemical/chemical research is consistent
with a mechanism involving the formation of a [Au-S,S-S], four-centered metallacycle
intermediate during the exchange (Figure 23)31.

Figure 23: Four-centered metallacycle intermediate
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Gold Thiolate, Disulfide Exchange Mechanism
In general, a proposed gold thiolate-disulfide exchange between insulin and either
Et3PAuSpy or Et3PAuSba can be seen in Figure 24 below where the first reactant is the
gold thiolate complex, the second reactant is insulin, the first product is an assumed gold
thiolate-insulin complex, and the other product is a mixed disulfide formed from the
thiolate ligand and the other part of the insulin that is not involved in the gold complex.

Et3PAu-SR + R’SSR’’ → Et3PAu-SR’ + RSSR’’
Figure 24: Predicted gold thiolate-disulfide exchange with an unsymmetrical disulfide

However, research has shown that gold-thiolates undergo exchange in a two-step manner,
first forming an unsymmetrical disulfide and then reacting this disulfide again to produce
a symmetric disulfide (Figure 25)8,34.

Figure 25: Two-step reaction of gold-thiolate with symmetric disulfide34.

Gold Thiolates as Disulfide Bond Cleavage Reagents
According to recent gas phase research, the high affinity of gold to sulfur suggests gold(I)
complexes may prove useful as disulfide cleavage reagents35. Possible sites of cleavage
are seen in Figure 26. It was found that disulfide bond (Figure 26 bond 1) cleavage
becomes less favorable as the size of the peptide increases35. The fragmentation is instead
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dominated by amide bond (Figure 26 bonds 3 and 4) cleavage via elimination of
CH2NH2, and no disulfide bond cleavage is observed36. This is because in comparison to
the energetics of simple amide bond cleavage, S-S bond cleavage reactions are higher in
energy24,36. However, out of all coinage metal systems studied, Me3PAu+ was superior in
promoting disulfide bond cleavage (60% S-S bond cleavage, where the second highest
was Ag with 10.8% S-S bond cleavage)35.

Figure 26: Possible bond cleavages in a disulfide bond between two cysteine residues35

A proposed electrophilic mechanism that was based on potential high S affinities and
previous studies was proposed by the Lioe research group (Figure 27). In the case of
insulin, one chain would form product A, while the other chain would form the cyclic
byproduct, where the β-chain is expected to contain a five-membered ring at each
cysteine location with the sulfur of the cysteine bound to the C-terminal amide nitrogen.

33

This is supported by further studies27. It is worthwhile to point out that this mechanism is
based on ionic versions of the metal complex and insulin and is also based on the method
of low-energy collision-induced dissociation (CID) reactions, which provide structural
information on peptides containing a disulfide bond37.

Figure 27: Proposed electrophilic neighboring group mechanism for the cleavage of disulfide bonds upon
the coordination of a metal complex to one of the sulfurs of the disulfide bond. X and Y are nearby amino
acids35.

Proteins as a Mode of Transport for Gold Thiolate Compounds
It is known that upon entering the body, Au(I) becomes bonded to cysteine sites in
glutathione, blood proteins and enzymes and is extensively distributed around the body
while undergoing rapid ligand displacement reactions8,38. It is known that most of the
circulating Au from antiarthritic drugs is bound to the cysteine-34 of serum albumin
(pKa~5) and transcription factors (Jun, Fos, NF-kB), which have cysteine residues
flanked by basic lysine and arginine residues2. Albumin can transfer Au(I) into cells via a
thiol shuttle mechanism7. When a phosphine gold ligand binds to Cys-34 of albumin, it
flips the cysteine residue from the buried pocket of albumin to the surface, where it is
more readily accessible (Figure 28)39.
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Figure 28: Structural transition induced by Au(I) in serum albumin39.

Since most gold drugs release the Et3PAu+ moiety in vivo, the other attachment in the
complex could potentially regulate the permeability into the cell and the ease of transport.

Gold Thiolate as Redox Buffer
If the formation of the DTT disulfide in this reaction is possible, then it is also possible
that an aromatic thiol or a gold thiolate could interact with DTT in the same way that
DTT interacts with aromatic thiols, namely a gold thiolate could be used to reduce the
DTT disulfide and shift the equilibrium of the reaction toward reduced disulfide.
However, phosphine gold(I) thiolate complexes have been shown to react with aromatic
disulfides via two pathways: 1) thiolate-disulfide exchange and 2) pathway that leads to
the formation of phosphine oxide34. These pathways are in competition. If gold thiolates
are reacting with aromatic disulfides, it could be possible that they may be reacting with
DTT disulfides after DTT reduces insulin.
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METHODS

Materials
Insulin (bovine, ≥ 25 USP units/mg (HPLC), powder) and K2HPO4 were acquired from
Alfa Aesar. Dithiothreitol (DTT) was acquired from Fluka BioChemika and Acros
Organics. Et3PAuCl, Trizma, d-Chloroform, DMSO, 4-mercaptobenzoic acid and 2mercaptopyridine were acquired from Sigma-Aldrich. EDTA, KH2PO4, HCl, and NaOH
were acquired from Fischer Scientific. Ethanol was acquired from Pharmco-Aaper.
Et3PAuSpy and Et3PAuSba were both synthesized in lab.

Preparation of insulin stock solution # 122
To prepare a 10 mg/mL insulin stock solution, 0.0250 g of bovine insulin was dissolved
in 4 mL of 0.05 M Tris-Cl buffer, pH 8.00, and adjusted to pH 2 by the addition of 1 M
HCl and rapidly titrated back to pH 8 with 1 M NaOH (about 4 drops each of HCl and
NaOH). The solution was then adjusted to 5 mL total volume with distilled water. The
stock solution was stored at freezing temperature.

Preparation of insulin stock solution # 21
To prepare a 0.167 mM insulin stock solution, 1 mL of a 10 mg/mL solution of insulin
(stock solution 1) was diluted to 8 ml with 0.1 M phosphate buffer. This cloudy solution
was made clear by adjusting to pH 3 by adding 1 M HCl dropwise and then rapidly
adjusting to pH 8 by adding 1 M NaOH dropwise. The final volume of insulin was
adjusted to 10 mL with distilled water. The stock solution was stored at freezing
temperature.
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RESULTS AND DISCUSSION

Each experiment contains a Methods section and a Results and Discussion section. It
seems more convenient to use this method of organization so that the reader can refer to
the components of the reaction vessel when reading the results and discussion.
Table 1: List of experiments, reactants and final concentrations in cuvette (mM). All experiments
conducted in a buffer were at pH 6.5 (buffer pH). Insulin’s pH is 8.

Experiment Name

Reactants

A

4-mercaptobenzoic acid, DTT,
insulin
DTT, insulin
4-mercaptobenzoic acid,
insulin
2-mercaptopyridine, DTT,
insulin
Et3PAuSpy, DTT, insulin
Et3PAuSpy, insulin
Et3PAuSpy, DTT
Et3PAuCl, insulin
Et3PAuCl, DTT

B
C
D
E
F
G
H
I

Final Concentration
in Cuvette (mM)
0.266, 0.333, 0.0556
0.333, 0.0556
0.266, 0.0556
0.266, 0.333, 0.0556
0.266, 0.333, 0.0556
0.266, 0.0556
varied (titration)
0.266, 0.0556
0.266, 0.333

Experiment A (4-mercaptobenzoic acid, DTT and insulin)
Methods: To prepare 20 mL of a 5.0 mM 4-mercaptobenzoic acid solution, 0.0154 g
(0.0999 mmol) were dissolved in 20 mL of phosphate buffer. The solution was stirred
and heated until all of the solid was dissolved in the solution. To prepare 20 mL of a 25.0
mM dithiothreitol solution, 0.0778 g (0.504 mmol) were dissolved in 20 mL of phosphate
buffer. The solution was stirred until all of the solid was dissolved in the solution. Insulin
stock solution 2 was warmed to room temperature. The UV-Vis was autozeroed on
phosphate buffer, not air. To make the cuvette solution, 1 mL of insulin stock solution 2
was added to the cuvette, followed by 1.8 mL of phosphate buffer, 160.0 µL of 4-
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mercaptobenzoic acid solution and 40.0 µL of dithiothreitol solution. The UV-Vis was set
up to scan the cuvette every 3 minutes (including the 25 sec it takes to actually perform a
scan) in the wavelength range of 300-800 nm. The total number of scans was 283
(approx. 14 hrs). The absorbance at 650 nm as a function of time in minutes was plotted
in Figure 29.
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Figure 29: Absorbance at 650 nm plotted as a function of time of the reaction between 4-mercaptobenzoic
acid, DTT and insulin. Graph shows the formation of a colloidal suspension of the α and β chains
precipitating out of solution. The plot shows a lag time, during which the particles are predicted to be
reaching a critical concentration and start aggregating after reaching it (200 min). Upon reaching the
maximum size of the aggregate, the particles start falling out of solution, becoming too dense to form a
colloidal suspension. This is evidenced by the decrease in light scatter at 820 min.

Results and Discussion: This experiment was carried out as a proof of concept of the
procedure for a thiol-mediated DTT reduction of insulin described by DeCollo and Lees1.
Because of a different total volume of this reaction from theirs (their total volume was 1.2
mL, while the total volume of the experiments in this study was 3 mL), the
concentrations of the reactants in this experiment differed from theirs, although the molar
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ratio was the same. In terms of a proof of concept, the reaction was a success, since there
was a colloidal suspension forming in the cuvette with time, increasing the light scatter
until the particles become too dense for the solution and begin falling. As reported by
Holmgren, there is a considerable lag time that occurs before the precipitation of the
chains in solution22, in this case, approximately 3 hours. A proposed mechanism for the
reaction between 4-mercaptobenzoic acid, insulin and DTT can be seen in Figure 30.
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Figure 30: Proposed mechanism for the reaction between 4-mercaptobenzoic acid, insulin and DTT, where
R1 and R2 are the α and β chains of insulin. DTT acts as a redox buffer, breaking the aromatic disulfide to
provide more 4-mercaptobenzoic acid to reduce insulin, thereby shifting the equilibrium of the reaction
toward reduced insulin. 4-mercaptobenzoic acid also acts as a redox buffer.

Experiment B (DTT and insulin)
Methods: To prepare 20 mL of a 25.0 mM dithiothreitol solution, 0.0777 g (0.504 mmol)
were dissolved in 20 mL of phosphate buffer. The solution was stirred until all of the
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solid was dissolved in the solution. Insulin stock solution 2 was warmed to room
temperature. The UV-Vis was autozeroed on phosphate buffer, not air. To make the
cuvette solution, 1 mL of insulin stock solution 2 was added to the cuvette, followed by
1.96 mL of phosphate buffer and 40.0 µL of dithiothreitol solution. The UV-Vis was set
up to scan the cuvette every 3 minutes (including the 25 sec it takes to actually perform a
scan) in the wavelength range of 300-800 nm. The total number of scans was 502
(approx. 25 hrs). The absorbance at 650 nm as a function of time in minutes was plotted
in Figure 31.
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Figure 31: Absorbance at 650 nm plotted as a function of time of the reaction between DTT and insulin.

Results and Discussion: This experiment was also done as a second proof of concept, as
DeCollo and Lees had carried out the reaction between DTT and insulin in order to
compare this reaction to the reaction of DTT and insulin in the presence of an aromatic
thiol in terms of relative rates. The comparison between Experiments A and B can be
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seen in Figure 33 and the relative rates can be seen as the slope of the linear fit on the
linear segment of both curves in Figure 34. The relative rate of experiment A is roughly
1.7 times that of experiment B, consistent with the results found by DeCollo and Lees,
that aromatic thiols increase the rate of the reduction of insulin by DTT. Lees reported a
relative rate of 1.6 between the reaction of 4-mercaptobenzoic acid, insulin and DTT
relative to insulin and DTT only1. A proposed mechanism for the reaction between DTT
and insulin can be seen in Figure 32.

Figure 32: Proposed mechanism for the reaction between insulin and DTT, where R1 and R2 are the α and β
chains of insulin.

4-mercaptobenzoic acid, DTT and insulin

DTT and insulin

0.35

Absorbance at 650 nm

0.3
0.25
0.2
0.15
0.1
0.05
0
0
-0.05

200

400

600

800

1000

1200

1400

Time (min)

Figure 33: Comparison between Experiment A (4-mercaptobenzoic acid, DTT and insulin) and Experiment
B (DTT and insulin)
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Figure 34: Comparison of the relative rates of Experiments A (4-mercaptobenzoic acid, DTT and insulin)
and B (DTT and insulin), where the linear range for Experiment A is 300-500 min and the linear range for
experiment B is 400-580 min.

Experiment C (4-mercaptobenzoic acid and insulin)
Methods: To prepare 20 mL of a 5.0 mM 4-mercaptobenzoic acid solution, 0.0154 g
(0.0999 mmol) were dissolved in 20 mL of phosphate buffer. The solution was stirred
and heated until all of the solid was dissolved in the solution. Insulin stock solution 2 was
warmed to room temperature. The UV-Vis was autozeroed on phosphate buffer, not air.
To make the cuvette solution, 1 mL of insulin stock solution 1 was added to the cuvette,
followed by 1.86 mL of phosphate buffer and 160.0 µL of 4-mercaptobenzoic acid
solution. The UV-Vis was set up to scan the cuvette every 3 minutes (including the 25
sec it takes to actually perform a scan) in the wavelength range of 300-800 nm. The total
number of scans was 483 (approx. 24 hrs).
Results and Discussion: This reaction was carried out over the course of 24 hours and
showed no result in the form of an increase in light scatter, suggesting either that there is
no reaction between 4-mercaptobenzoic acid and insulin or that it has a significantly
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reduced rate and therefore has a considerably long lag time. Lees does not report the
relative rates of this experiment to others.
Changing the Thiol
During synthesis of the proposed Et3PAuSba compound, to be used in later studies, it was
found that the compound is not soluble in phosphate buffer. This undermines the
experiment as the compound will precipitate out of solution when put in the cuvette for a
reaction. Instead, it was proposed to switch the thiol from 4-mercaptobenzoic acid to 2mercaptopyridine, since Et3PAuSpy was known to be at least partially soluble in
phosphate buffer.
Experiment D (2-mercaptopyridine, DTT and insulin)
Methods: To prepare 20 mL of a 5 mM solution of 2-mercaptopyridine, 0.0216 g (0.194
mmol) were dissolved in 20 mL of buffer. The solution was stirred until all of the solid
was dissolved in the solution. To prepare 20 mL of a 25.0 mM dithiothreitol solution,
0.0768 g (0.498 mmol) were dissolved in 20 mL of phosphate buffer. The solution was
stirred until all of the solid was dissolved in the solution. Insulin stock solution 2 was
warmed to room temperature. The UV-Vis was autozeroed on phosphate buffer, not air.
To make the cuvette solution, 1 mL of insulin stock solution 2 was added to the cuvette,
followed by 1.8 mL of phosphate buffer, 160.0 µL of 2-mercaptopyridine solution and
40.0 µL of dithiothreitol solution. The UV-Vis was set up to scan the cuvette every 3
minutes (including the 25 sec it takes to actually perform a scan) in the wavelength range
of 300-800 nm. The total number of scans was 243 (approx. 12 hrs). The absorbance at
650 nm as a function of time in minutes was plotted in Figure 35.
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Figure 35: Absorbance at 650 nm plotted as a function of time of the reaction between 2-mercaptopyridine,
DTT and insulin.

Results and Discussion: This reaction was compared to Experiment A, as the only change
from Experiment A to D was the switch of the thiol used in the experiment. The
comparison can be seen in Figure 36. The new thiol (2-mercaptopyridine) seems to be
catalyzing the reduction of insulin by DTT in the same manner, and so is a viable
substitute. The proposed mechanism for the reaction between 2-mercaptopyridine, DTT
and insulin can be seen in Figure 37. The mechanism is based on the known mechanism
for Experiment A, substituting the 4-mercaptobenzoic acid for 2-mercaptopyridine,
which has been shown in Figure 36 to have the same effect on the reaction between
insulin and DTT.
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Figure 36: Comparison between Experiment A (4-mercaptobenzoic acid, DTT and insulin) and Experiment
D (2-mercaptobenzoic acid, DTT and insulin).
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Figure 37: Proposed mechanism between 2-mercaptopyridine, insulin and DTT, where R1 and R2 are the α
and β chains of insulin. DTT acts as a redox buffer, breaking the aromatic disulfide to provide more 2mercaptopyridine to reduce insulin, thereby shifting the equilibrium of the reaction toward reduced insulin.
The two thiols of DTT act as an oxidation-reduction couple, in the same way as PDI’s two active site
cysteine residues act together40.

Experiment E (Et3PAuSpy, DTT and insulin)
Methods: To prepare 1 mL of a 5.0 mM Et3PAuSpy solution, 0.0021 g (0.0049 mmol)
were dissolved in 0.2 mL of dimethyl sulfoxide and diluted to 1 mL with phosphate
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buffer. The solution was stirred until all of the solid was dissolved in the solution. To
prepare 20 mL of a 25.0 mM dithiothreitol solution, 0.0781 g (0.5063 mmol) were
dissolved in 20 mL of phosphate buffer. The solution was stirred until all of the solid was
dissolved in the solution. Insulin stock solution 2 was warmed to room temperature. The
UV-Vis was autozeroed on phosphate buffer, not air. To make the cuvette solution, 1 mL
of insulin stock solution 2 was added to the cuvette, followed by 1.8 mL of phosphate
buffer, 160.0 µL of Et3PAuSpy solution and 40.0 µL of dithiothreitol solution. The UVVis was set up to scan the cuvette every 3 minutes (including the 25 sec it takes to
actually perform a scan) in the wavelength range of 300-800 nm. The total number of
scans was 273 (approx. 14 hrs). The absorbance at 650 nm as a function of time in
minutes was plotted in Figure 38.
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Figure 38: Absorbance at 650 nm plotted as a function of time of the reaction between Et3PAuSpy, DTT
and insulin.
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Results and Discussion: This experiment was carried out to see if replacing a thiol with a
gold thiolate would have the same effect in terms of increasing the rate of the reaction
between DTT and insulin. It appears that Et3PAuSpy increases the rate of the reaction
between insulin and DTT more so than 2-pyridinethiol (Figure 40). In order to compare
the effect Et3PAuSpy has on the reaction, the comparison between Experiment B and
Experiment E needs to be made (Figure 41). As can be seen in this graph, Et3PAuSpy
considerably reduces the lag time of the reaction, as well as noticeably increasing the
rate.

Similar to how DTT shifted the equilibrium toward reduced insulin when an aromatic
thiol was combined with insulin in the presence of DTT, it is possible that DTT has the
same function in this experiment (see Figure 43).
The offset in the two slopes in Figures 40 and 41 is most likely due to the possibility of
two separate mechanisms that form different kinds of particles that aggregate at different
rates. This supposition is based on the knowledge that Et3PAuSpy reacts with DTT to
form 2-pyridinethiol (Experiment G) and the knowledge that Et3PAuSpy also reacts with
insulin to form a colloidal suspension that scatters light at 650 nm (Experiment F). These
results suggest an explanation for the initial increase in light scatter, followed by a lag
time and then again an increase until reaching a maxima in the graph of Figure 38, which
shows the reaction between Et3PAuSpy, DTT and insulin.
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Figure 40: Comparison between experiments D (2-pyridinethiol, DTT and insulin) and E (Et3PAuSpy, DTT
and insulin)
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Figure 41: Comparison between experiments B (DTT and insulin) and E (Et3PAuSpy, DTT and insulin)
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Experiment F (Et3PAuSpy and insulin)
Methods: To prepare 1 mL of a 5.0 mM Et3PAuSpy solution, 0.0021 g (0.0049 mmol)
were dissolved in 0.2 mL of dimethyl sulfoxide and diluted to 1 mL with phosphate
buffer. The solution was stirred until all of the solid was dissolved in the solution. Insulin
stock solution 2 was warmed to room temperature. The UV-Vis was autozeroed on
phosphate buffer, not air. To make the cuvette solution, 1 mL of insulin stock solution 2
was added to the cuvette, followed by 1.86 mL of phosphate buffer and 160.0 µL of
Et3PAuSpy solution. The UV-Vis was set up to scan the cuvette every 3 minutes
(including the 25 sec it takes to actually perform a scan) in the wavelength range of 300800 nm. The total number of scans was 241 (approx. 12 hrs). The absorbance at 650 nm
as a function of time in minutes was plotted in Figure 42.
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Figure 42: Absorbance at 650 nm plotted as a function of time of the reaction between Et3PAuSpy and
insulin
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Results and Discussion: This experiment was carried out to control for DTT. If insulin
reacts with Et3PAuSpy itself, without needing DTT as a reducing agent, then the
mechanism of the reaction gets more complicated, proposing the idea that there is more
than one reaction happening when Et3PAuSpy, DTT and insulin are mixed together. As
can be seen in Figure 42, insulin does react with Et3PAuSpy, and at a noticeably faster
rate than the other reactions that have been investigated in this study. In comparison to
the reaction with DTT, the reaction without DTT is much faster (Figure 44). The
proposed mechanism for this reaction can be seen in Figure 43. The mechanism is based
on the knowledge that gold-sulfur compounds undergo thiolate-disulfide exchange by
forming a metallacycle intermediate with a disulfide. The shape of the graphs in Figure
44 is very different, with drastically different maxima, possibly indicating that the size of
the particles grows more rapidly with gold.

Figure 43: Proposed mechanism for the reaction between Et3PAuSpy and insulin, where R1 and R2 are the α
and β chains of insulin.

52

Et3PAuSpy and insulin with and without DTT
Et3PAuSpy and insulin
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Figure 44: Comparison of experiments E (Et3PAuSpy, DTT and insulin) and F
(Et3PAuSpy and insulin)

Experiment G (Et3PAuSpy and DTT)
UV-Vis:
Method: To prepare 10 mL of 3 mM solution of dithiothreitol, 0.0048 g (0.0311 mmol)
were dissolved in 10 mL of ethanol. To make this solution more dilute for UV-Vis, 0.5
mL of the 3 mM solution were diluted to a volume of 3 mL with ethanol. To prepare 3
mL of a 1 mM solution of Et3PAuSpy, 0.0029 g (0.0068 mmol) were dissolved in
ethanol. To make this solution more dilute for UV-Vis, 1 mL of the 1 mM solution was
diluted to a volume of 14 mL with ethanol. The concentrations of Et3PAuSpy and
dithiothreitol before titration were 0.1 mM and 0.5 mM respectively. About 2 mL of the
0.5 mM solution of Et3PAuSpy was transferred to the cuvette and scanned (Et3PAuSpy in
Figure 46). Then, the solution in the cuvette was titrated with the 0.1 mM solution of
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dithiothreitol by adding one drop at a time and scanning the solution, to create the graph
in Figure 45. The range of UV-Vis was 200-500 nm.
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Figure 45: Absorbance plotted as a function of wavelength (nm) of Et3PAuSpy with DTT, added dropwise

Results and Discussion: Experiment G was carried out to look at the possible reaction
between Et3PAuSpy and DTT. The UV-Vis data was acquired using a titration of
Et3PAuSpy with DTT added dropwise to a solution of Et3PAuSpy over a period of 30
minutes. Figure 45 shows the absorbance at 3, 6, 9 and 12 drops of DTT added to the
cuvette. It can be observed from the graph that Et3PAuSpy is converted to 2-pyridinethiol
in the reaction with DTT with three isosbestic points at approximately 227, 300 and 327
nm. A comparison of the initial spectra of 2-pyridinethiol, DTT and Et3PAuSpy with the
reaction solution of Et3PAuSpy and DTT is made in Figure 46. It is clear from just
comparing the reaction solution with the spectrum of 2-pyridinethiol that it is a
conversion of Et3PAuSpy to 2-pyridinethiol because of the way the peaks are lined up
one on top of the other. The 1H NMR data also supports this conclusion (Figures 47-50).
Table 2 (in conjunction with Figure 51) summarizes the 1H NMR data and gives a
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thorough comparison of the three spectra. It is clear that Et3PAuSpy is left over after the
reaction is finished, due to the peaks associated with Et3PAuSpy still being present in the
reaction spectrum (Figure 49). However, two new peaks have appeared in the reaction
spectrum (Figure 49) that are not attributed to either DTT or Et3PAuSpy. These peaks (c
and d as labeled on 2-pyridinethiol) are indications that 2-pyridinethiol has dissociated
from the gold complex. 2-pyridinethiol should also theoretically have a peak at 8.62 ppm
that integrates for the e proton, but it is not observed on the spectrum of 2-pyridinethiol,
which might be a signal to noise ratio problem. There are a couple of impurities in the
spectra and several water peaks, but those have been carefully specified in the table. The
thiol peaks from 2-pyridinethiol are not observed in addition to the missing DTT OH
group peaks, which is common for 1H NMR spectra. It is proposed from the data that
peak 6 for Et3PAuSpy is the combination of 2-pyridinethiol’s peaks 6 and 7 (the chemical
shift due to gold’s electron-withdrawing character). It is also proposed that the reaction
between Et3PAuSpy and DTT could form the disulfide pictured in Figure 53. However,
this hypothesis can be rejected due to the following two reasons: 1) one of the 1H NMR
peaks for the disulfide (Figure 52) at 8.5 ppm is not observed in the reaction spectrum
and 2) while literature values for the UV absorbance for the disulfide show two peaks
(238 and 282 nm) (31), the 238 nm peak is not observed in the reaction UV spectrum.
Both of these reasons support the conclusion that the disulfide was not a product of the
reaction between Et3PAuSpy and DTT.
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Figure 46: Comparison of 2-pyridinethiol, DTT, Et3PAuSpy and the reaction of DTT and Et3PAuSpy

1

H NMR:
This reaction was also investigated by 1H NMR, by first acquiring a 1H NMR scan of the
reactants and then mixing them in a 1:1 volume equivalent and acquiring a scan of the
solution in CDCl3 (Figures 47-50).
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Figure 47: 1H NMR spectrum of Et3PAuSpy in CDCl3
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Figure 48: 1H NMR spectrum of DTT in CDCl3
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Figure 49: 1H NMR spectrum of the reaction between DTT and Et3PAuSpy in CDCl3
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Figure 50: 1H NMR spectrum of 2-pyridinethiol in CDCl3
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Table 2: Location of peaks on 1H NMR spectrum and indicated protons
Et3PAuSpy

DTT

Et3PAuSpy + DTT

2-pyridinethiol

Peak

Location
(ppm)

Proton
Designation

Location
(ppm)

Proton
Designation

Location
(ppm)

Proton
Designation

Location
(ppm)

Proton
Designation

1

1.21

a,c,e

1.5

a,h

1.2

1.24

Impurity

2

1.55

Water

2.62.75

b,g

1.57

1.56

Water

3

1.87

b,d,f

3.7

c,e

1.88

3.71

Impurity

4

6.80

g

7.25

CDCl3

2.75

A,c,e
(Et3PAuSpy)
Water
(broad peaknot DTT)
B,d,f
(Et3PAuSpy)
b,g (DTT)

6.74

b

5

7.25

CDCl3

-

-

3.75

c,e (DTT)

7.25

CDCl3

6

7.45

i,h

-

-

6.8

7.37

c

7

8.22

j

-

-

7.0

g
(Et3PAuSpy)
Impurity

7.56

d

8

-

-

-

-

7.2

Impurity

12.93

9

-

-

-

-

7.25

CDCl3

-

Impurity
(OH)
-

10

-

-

-

-

7.3

Impurity

-

-

11

-

-

-

-

7.37

c (2-pyr)

-

-

12

-

-

-

-

7.55

d (2-pyr)

-

-

13

-

-

-

-

8.2

j
(Et3PAuSpy)

-

-

Figure 51: Proton labeling from left to right: Et3PAuSpy, DTT and 2-pyridinethiol
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Figure 52: 1H NMR spectrum of 2-pyridinethiol disulfide (SciFinder)

Figure 53: Possible 2-pyridinethiol disulfide

Oxidized DTT
DTT is unstable in its reduced form and its oxidation can be further catalyzed by metal
ions41. A study in 2013 showed that the redox potential of the reaction changed by 3-5%
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during the 2.5 hrs needed for the reactions investigated41. Even though it has often been
assumed that under anaerobic conditions and in the presence of a chelating agent such as
EDTA the reaction should maintain a constant redox potential, the 2013 study proved this
assumption false41. In general, this should not be an issue at small enough concentrations
of DTT; however, the possibility of DTT oxidizing while sitting in solution for some time
was tested by UV-Vis. The solution of DTT used for the titration was scanned initially
and after 30 minutes. Unlike reduced DTT, which is not UV active, oxidized DTT is UV
active with an absorbance peak at 283 nm (Figure 54)14. The scan of the DTT solution
after sitting for 30 minutes showed no absorbance peak, therefore suggesting that DTT
does not oxidize while sitting in solution for the amount of time required to do the
titration of Et3PAuSpy with DTT (Figure 55).

Figure 54: Molar absorbance of oxidized DTT as a function of wavelength. Solvent is 0.05 M phosphate
buffer, pH 814.
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Figure 55: UV-Vis scan of the DTT solution right after it was made and after it has been sitting uncovered
for 30 minutes (the time interval it took for the titration), showing no oxidizing activity, as DTTred is not
UV-active, while DTTox is UV-active (peak at 282 nm).

Experiment H (Et3PAuCl and insulin)
Methods: To prepare 3.7 mL of a 5.0 mM Et3PAuSpy solution, 0.0065 g (0.0185 mmol)
were dissolved in phosphate buffer. The solution was stirred until all of the solid was
dissolved in the solution. Insulin stock solution 2 was warmed to room temperature. The
UV-Vis was autozeroed on phosphate buffer, not air. To make the cuvette solution, 1 mL
of insulin stock solution 2 was added to the cuvette, followed by 1.86 mL of phosphate
buffer and 160.0 µL of Et3PAuCl solution. The UV-Vis was set up to scan the cuvette
every 3 minutes (including the 25 sec it takes to actually perform a scan) in the
wavelength range of 300-800 nm. The total number of scans was 242 (approx. 12 hrs).
The absorbance at 650 nm as a function of time in minutes was plotted in Figure 56.
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Figure 56: Absorbance at 650 nm plotted as a function of time of the reaction between Et3PAuCl and
insulin

Results and Discussion: Experiment H was carried out to see how Et3PAuCl would react
with insulin. According to the UV spectrum above, Et3PAuCl does react with insulin, but
the four-centered metallacycle intermediate mechanism proposed for the reaction
between Et3PAuSpy and insulin does not seem likely in this case, due to the nature of
Et3PAuCl, which usually undergoes a ligand-substitution. However, the thiol-containing
amino acid cysteine was found to react with bromo(triethylphosphine)gold in aqueous
solution42. The product, 2-amino-2-carboxyethylthio(triethylphosphine)gold (Figure 57)
was unstable and its aqueous solution slowly deposited an amorphous precipitate of
aurous cysteinate42. A freshly made solution of the product was acidified with
hydrochloric acid to give cysteine and chloro(triethylphosphine)gold42. This seems to
suggest that Et3PAuCl can react with the cysteine residues of insulin in the same manner,
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that is if the cysteines were free and were not part of disulfide bonds. It is possible that
Et3PAuCl may be interacting with nearby amino acids that have donor atoms, such as
histidine. However, a mechanism for this reaction cannot be gleaned at this point in the
research.

Figure 57: Structure of 2-amino-2-carboxyethylthio(triethylphosphine)gold

Experiment I (Et3PAuCl and DTT)
UV-Vis:
Methods: To prepare 10 mL of 3 mM solution of dithiothreitol, 0.0046 g (0.0298 mmol)
were dissolved in 10 mL of ethanol. To make this solution more dilute for UV-Vis, 0.5
mL of the 3 mM solution were diluted to a volume of 3 mL with ethanol. To prepare 10
mL of a 1 mM solution of Et3PAuCl, 0.0035 g (0.0099 mmol) were dissolved in ethanol.
To make this solution more dilute for UV-Vis, 1 mL of the 1 mM solution was diluted to
a volume of 15 mL with ethanol. The final concentrations of Et3PAuCl and dithiothreitol
were 0.1 mM and 0.5 mM respectively. About 2 mL of the 0.1 mM solution of Et3PAuCl
was transferred to the cuvette and scanned, showing no peak, which was expected as
Et3PAuCl is not UV active. Then, the solution in the cuvette was titrated with the 0.5 mM
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solution of dithiothreitol by adding one drop at a time and scanning the solution. The
range of UV-Vis was 200-500 nm. There were no observable peaks as more DTT was
added dropwise, suggesting that DTT does not react with Et3PAuCl.
1

H NMR:

To confirm this hypothesis, the reaction was also investigated using 1H NMR, by first
acquiring a 1H NMR scan of the reactants and then mixing them in a 1:1 volume
equivalent and acquiring a scan of the solution in CDCl3 (Figures 59-61). Table 3 in
conjunction with Figure 62 summarize the 1H NMR data and give a comparison between
reactants and the reaction solution.
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Figure 59: 1H NMR spectrum of Et3PAuCl in CDCl3
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Figure 60: 1H NMR spectrum of DTT in CDCl3
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Figure 61: 1H NMR spectrum of the reaction between Et3PAuCl and DTT in CDCl3

Table 3: Location of peaks on 1H NMR spectrum and indicated protons

Et3PAuCl
Peak Location
(ppm)
1
1.19

DTT
Proton
Location
Designation (ppm)
a,d,f
1.49

2

1.54

Water

2.73

3

1.83

b,c,e

3.66

4
5
6
7

5.29
7.25
-

Impurity
CDCl3
-

5.29
7.25
-
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Et3PAuCl + DTT
Proton
Location
Proton
Designation (ppm)
Designation
a,h
1.19
a,d,f
(Et3PAuCl)
b,g
1.49-1.56 a,h (DTT)
and water
c,e
1.83
b,c,e
(Et3PAuCl)
Impurity
2.62-2.74 b,g (DTT)
CDCl3
3.66
c,e (DTT)
5.29
Impurity
7.25
CDCl3

Figure 62: Proton labeling from left to right: Et3PAuCl and DTT

Results and Discussion: Experiment I was carried out to compare the reaction between
DTT and Et3PAuCl (Experiment H) and DTT and Et3PAuSpy (Experiment I). Et3PAuCl
and reduced DTT are not UV-Vis active, and therefore show no absorbance. The goal of
the experiment was to observe using UV-Vis the possible appearance of a peak to
indicate the formation of a product. No such peak appeared. The 1H NMR data showed
that the reaction solution of DTT and Et3PAuCl showed all of the peaks that DTT and
Et3PAuCl showed separately and no chemical shifts were observed. The peak at 5.29
ppm was a methylene chloride peak that showed reagent bottle contamination. It seems
plausible from UV and 1H NMR data that Et3PAuCl and DTT do not react. Since
Et3PAuCl and DTT would have reacted through a simple ligand substitution, it seems like
Et3PAuSpy and DTT do not go through a ligand substitution mechanism.
Furthermore, it is possible that the DTT forms a complex with Et3PAuCl, whereby it
links two of the molecules together (Figure 63)43. However, since there is no indication of
chemical shifts, there is no reason to think the dimer was formed.
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Figure 63: Possible product of the reaction between Et3PAuCl and DTT

It is useful to mention that dithioerythritol (DTE), an isomer of DTT was successfully
reacted with Et3PAuCl in a 50/50 mixture of ethanol and water under vigorous stirring to
form a white precipitate in one study43. An indicator that the reaction occurred was the
sudden acidification of the solution43. It is possible that Et3PAuCl may react with DTT
under likewise conditions.
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DISCUSSION

Approximately 20% of all human proteins are predicted to contain disulfide bonds4. With
this abundance in the human organism, it is important to study thiol-disulfide exchange
reactions using biological models to gain insight into how disease-specific drugs may be
interacting with proteins in the body. By looking at how gold thiolates interact with
protein disulfides using insulin as a model protein disulfide, this experiment was able to
look at how gold thiolates might be interacting with biological disulfides in a gold
thiolate-disulfide exchange reaction.

The study was started by replicating two experiments performed by the Lees research
group, namely the reaction between 4-mercaptobenzoic acid, DTT and insulin compared
to the reaction between DTT and insulin. The method of data collection used was UV-Vis
spectroscopy, but it was used to observe light scatter at 650 nm, instead of the usual
absorbance method. When the disulfide bonds in insulin are reduced, the two chains of
insulin break apart, forming a colloidal suspension. This suspension scatters light at 650
nm, which provides a curve that shows an initial lag time (which can be attributed to the
particles not having yet reached a critical concentration at which they start aggregation),
followed by a steady increase in light scatter (aggregation), which is directly proportional
to the extent to which the insulin disulfide bonds have been broken. After reaching a
certain maximum, the particles become too dense to stay in the colloidal suspension and
sink to the bottom, which is why the rate of particle formation decreases after reaching a
maximum. The relative rate that was acquired during this study (approximately 1.7) was
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close to the value reported by Lees of 1.6, showing that 4-mercaptobenzoic acid catalyzes
the reaction between DTT and insulin. This was a good starting point for the study, and
the results are depicted in Experiments A and B. The next step of the study was to see if
4-mercaptobenzoic acid would break the disulfide bonds in insulin without the assistance
of DTT. Experiment C showed no reaction as monitored by UV-Vis over 24 hours. This
suggested that either 4-mercaptobenzoic acid does not react with insulin, or that the lag
time of the reaction is very long and is beyond the scope of the 24 hours that was
dedicated to the reaction.

The next step of the study was to try a gold thiolate in the reaction between DTT and
insulin to see if the gold compound would have the same effect as the aromatic thiol used
previously (4-mercaptobenzoic acid). However, when synthesized, Et3PAuSba was not
soluble in phosphate buffer, which was the solvent system that was being used for the
experiments. Thus, it became necessary to change the thiol that was being investigated,
so that once the gold thiolate that had the thiol moiety attached to it was synthesized, it
would be soluble in phosphate buffer. This would ensure that all reactants were fully
soluble in the solvent and any precipitation observed would be caused by the breaking of
the disulfide bonds in insulin and the formation of the colloidal suspension of α and β
chain particles. The thiol that was picked as a replacement was 2-mercaptopyridine,
which was available in lab, and it was known that Et3PAuSpy was soluble in phosphate
buffer. Experiment D was conducted to observe the reaction between 2mercaptopyridine, DTT and insulin. A comparison was made between 2mercaptopyridine’s and 4-mercaptobenzoic acid’s effect on the rate of the reaction

74

between DTT and insulin. The graphs of these two experiments were nearly completely
overlapping, suggesting similar results for effect on the rate of the reaction between DTT
and insulin.

The next step of the study was to see what effect the gold thiolate would have on the rate
of the reaction between DTT and insulin. This was the purpose of Experiment E. The
graph obtained showed an initial increase, followed by a drastic decrease in slope, yet
still increasing for some time and then another drastic increase in slope. This kind of
graph was a surprise, because it indicated the possibility that there could be several
mechanisms at work when combining Et3PAuSpy, DTT and insulin. As was found by
Experiments E and F, which looked at the reaction between Et3PAuSpy and insulin and
the reaction between Et3PAuSpy and DTT respectively, these reactions were occurring by
different mechanisms. The reaction between Et3PAuSpy and insulin produced the
familiar colloidal suspension of α and β chain particles. The reaction between Et3PAuSpy
and DTT was shown to produce 2-mercaptopyridine by both UV-Vis and 1H NMR. This
suggests that the prediction about Experiment E (Et3PAuSpy, DTT and insulin), namely
that there might be several competing mechanisms that give the different shape of the
graph, might have merit.

The next step in the study was to look at how Et3PAuCl would react with insulin. This
was the purpose of Experiment H. The graph of the experiment showed the formation of
a colloidal suspension, but several breaks in the graph suggest either instrument
malfunction or possibly interesting particle formation dynamics. Since the experiment
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was not replicated, it is hard to say which of those is more plausible. The reproducibility
aspect is addressed further below. The observation that Et3PAuCl reacts with insulin
makes analysis harder, since Et3PAuCl would not break the disulfide bonds by thioldisulfide exchange and would instead want to participate in a ligand-substitution reaction.
This makes the results of this experiment interesting, because it suggests that Et3PAuCl is
interacting with other amino acids in insulin, possibly such donor atom-containing amino
acids as histidine. Lastly, Experiment I was conducted to look at the possible reaction
between Et3PAuCl and DTT. Neither UV-Vis nor 1H NMR showed that a reaction was
occurring. It is possible that the conditions in which the reaction was conducted were not
optimal. DTT has to be deprotonated under basic conditions to react, and the UV-Vis
reaction was conducted in methanol, which is technically an acid and a base at the same
time. The 1H NMR reaction was carried out in deuterated chloroform, which is acidic
because of the induction affects from the chloride groups. It is possible that DTT did not
have a chance to be deprotonated and thus was not able to react.
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CONCLUSION

As far as specific conclusions that could be made from this study, they are as follows: 1)
4-mercaptobenzoic acid and 2-mercaptopyridine catalyze the reaction between DTT and
insulin, likely by the same mechanism, as supported by the Lees research group findings
and UV-Vis data. 2) Et3PAuSpy seems to catalyze the reaction between DTT and insulin
more so than the aromatic thiols, although it was also seen reacting with insulin directly,
with no DTT present. Et3PAuSpy was also shown to react with DTT to produce 2pyridinethiol. As of now, it is unclear as to how the three of them react in solution. It is
predicted that once all three are combined in solution, there are several competing
mechanisms that occur together. 3) Et3PAuCl and insulin were shown to react. It is
predicted that Et3PAuCl reacts with donor atom-containing amino acids in insulin such as
histidine, which could cause precipitation of insulin molecules.
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FUTURE WORK

An important point to consider is that while these studies are concerned with observing
the reaction between insulin and a variety of thiols and thiolates, the reaction happens in a
phosphate buffer system. One of the reasons this research is important is to facilitate the
purification and correct refolding of disulfide-containing proteins from recombinant
inclusion bodies (insoluble protein aggregates)44. However, the folding of inclusion
bodies of disulfide-containing proteins is typically performed in the presence of a
denaturant such as guanidine hydrochloride or urea, while this research was not
conducted with a denaturant present44. It is, however, important to point out that studies
on the reaction between RNase A and small ortho- and meta-substituted aromatic thiols
in the presence of denaturants provided 100% recovery of active protein without
significant alteration of protein-folding rates44. It would be interesting to see whether
gold thiolates would have the same effect.

Additionally, the experiments performed in this study have not been replicated to the
extent as to be able to talk about error and reproducibility. The first two experiments
(Experiment A: 4-mercaptobenzoic acid, DTT and insulin; Experiment B: DTT and
insulin) have been done by the Lees research group, and their relative rate of 1.6 showed
that 4-mercaptobenzoic acid catalyzed the breaking of the insulin disulfide bonds,
therefore increasing the rate of the formation of the colloidal suspension. The results of
Experiments A and B give an approximate relative rate of 1.7, which is close to the Lees
relative rate of 1.6. This suggests that Experiments A and B reproduced the results
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acquired by the Lees research group. However, to be certain that the conclusions of this
study are valid, each experiment would need to be replicated at least 3-4 times to be able
to calculate the mean rate and the standard deviation from the mean to be able to discuss
precision and reproducibility. Especially experiments that had unexpected artifacts or
outcomes (such as Experiment H, Figure 56) would need to be replicated to see whether
those artifacts (such as breaks in the graph) are due to improper instrumentation function
or are indications of complicated mechanisms that would warrant further study of the
reaction. The reaction of Et3PAuCl with DTT was also most likely conducted under
improper conditions, as DTT has to be deprotonated under basic conditions, while the
two solvents used for the UV-Vis and 1H NMR experiments were methanol and
deuterated chloroform respectively. This could provide nonideal conditions for this
reaction and it might thus be possible to react Et3PAuCl with DTT under different
conditions.

The factors that have been shown to be important advantages for protein folding catalysts
as indicated by Lees are as follows:
1) Low thiol pKa (strongly acidic thiol, weakly basic thiolate-close to physiological
pH), a pKa of approximately 1 unit less than the pH of the solution has been
found to be optimal for protein folding, with increased thiolate reactivity4
2) Low reduction potential (allows the catalyst to exist as a nearly 50:50 mixture of
thiol and disulfide for efficient protein folding)4
3) Dithiol over a monothiol (dithiols discourage forming long-lived mixed disulfides
between the folding catalyst and the protein of interest)
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4) Aromatic thiols increase the rate of folding by at least three times as opposed to
aliphatic thiols
In developing more efficient protein folding catalysts it is important to keep these factors
in mind. In the case of gold thiolates, a possible development of an aromatic gold dithiol
with a low pKa might be advantageous for further studies in regard to the redox buffer.

A look at the different variables that can be changed in the study is also warranted.
Studies can be designed that change variables that were kept constant during this study
but might shed some light on the results. For example, it might be interesting to look at
the way the rate of formation of the colloidal suspension (the rate of disulfide bond
breakage) changes when the reaction is stirred, when the temperature is changed or when
the pH is changed (keeping in mind that insulin is only soluble in a buffer of pH 6-8).
These studies could account for such things as diffusion (since the reactions were not
stirred in this experiment) and the mean aggregation rate could be acquired instead of the
initial rate.

Insulin is used as a model protein because it has three disulfide bonds and is readily
commercially available; however, the study can be opened to other proteins containing
disulfides. Other methods of data collection might also prove more optimal than light
scatter, such as Particle Size Distribution, which could shed some light on such reactions
as Et3PAuSpy, DTT and insulin, which is predicted to react in several different
competing mechanisms (Et3PAuSpy reacts both with DTT and insulin, and DTT reacts
with insulin as well, all react by different mechanisms). Other useful techniques could be
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HPLC (to look at the formation of oxidized DTT) or mass spectrometry, which would
further the studies previously discussed in the Introduction, and in which Me3PAu+
proved a very promising compound for the breaking of disulfide bonds in gas-phase
reactions.
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